Lentiviral, adenoviral, and adeno-associated viral vectors will be designed for validation of selected lymphangiogenic genes in vivo. Gene overexpression of growth factors and soluble receptors will be utilized in models of lymphedema and tumour metastasis.

 

 

Participating consortium partners:

 

® Dr. Kari Alitalo, University of Helsinki, Finland

® Dr. Hellmut Augustin, German Cancer Research Center, Heidelberg, Germany

® Dr. Lena Claesson-Welsh, Uppsala University, Sweden

® Dr. Jyrki Ingman, Lymphatix Ltd., Helsinki, Finland

® Dr. Dontscho Kerjaschki, Medical University of Vienna, Austria